Leukemia treatment breakthrough: could less be more for responding patients?
Disease control
Recruiting now
This study tests whether adults with acute myeloid leukemia (AML) who have responded well to a year of venetoclax and azacitidine can safely stop these drugs. Fifty participants will discontinue treatment and be closely monitored for relapse. The goal is to see if stopping therap…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC